A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Annemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlan...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/da3dc5653ea84b31b93ae7785389c2bf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:da3dc5653ea84b31b93ae7785389c2bf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:da3dc5653ea84b31b93ae7785389c2bf2021-12-02T00:22:15ZA combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension1177-5483https://doaj.org/article/da3dc5653ea84b31b93ae7785389c2bf2016-04-01T00:00:00Zhttps://www.dovepress.com/a-combined-analysis-of-four-observational-studies-evaluating-the-intra-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Annemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlands; 4Allergan Holdings Ltd, Marlow, UK; 5Private Office, Vienna, Austria Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. Keywords: bimatoprost 0.01%, intraocular pressure, prostaglandin, bimatoprost, glaucoma treatment, switch therapyStevens AIliev MEde Jong LGrobeiu IHommer ADove Medical Pressarticlebimatoprost 0.01%intraocular pressureprostaglandinbimatoprostglaucoma treatmentswitch therapyOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 635-641 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
bimatoprost 0.01% intraocular pressure prostaglandin bimatoprost glaucoma treatment switch therapy Ophthalmology RE1-994 |
| spellingShingle |
bimatoprost 0.01% intraocular pressure prostaglandin bimatoprost glaucoma treatment switch therapy Ophthalmology RE1-994 Stevens A Iliev ME de Jong L Grobeiu I Hommer A A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| description |
Annemie Stevens,1 Milko E Iliev,2 Leo de Jong,3 Ioana Grobeiu,4 Anton Hommer5 1Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium; 2Department of Ophthalmology, University of Bern, Bern, Switzerland; 3Department of Ophthalmology, Academic Medical Centre, Amsterdam, the Netherlands; 4Allergan Holdings Ltd, Marlow, UK; 5Private Office, Vienna, Austria Objective: Combine and evaluate data from four clinical practice studies investigating the intraocular pressure (IOP)-lowering ability, tolerability of and patient adherence to bimatoprost 0.01% therapy in patients with primary open-angle glaucoma or ocular hypertension. Methods: Data were combined from four multicenter, prospective, observational studies. Patients (n=2,593) were recruited from 328 sites in Austria, Belgium, Switzerland, and the Netherlands. Assessments were at study entry (baseline) and after 10–14 weeks. Results: Bimatoprost 0.01% lowered mean IOP by 5.0 mmHg from baseline to final visit (P<0.0001). Individual IOP goals were achieved in 75.5% of patients. Results were similar in right and left eyes; right-eye data are presented here for brevity. The greatest mean IOP reduction was 6.7±4.7 mmHg (28.8% reduction from baseline to final visit, P<0.0001) in treatment-naïve patients. Switching to bimatoprost 0.01% monotherapy from previous monotherapy reduced mean IOP by a further 3.2±3.6 mmHg (17.2%, P<0.0001). Switching to bimatoprost 0.01% from previous prostaglandin monotherapy reduced mean IOP by 2.9±3.5 mmHg (15.5%), including by 3.1±3.4 mmHg (15.8%) and 3.3±4.1 mmHg (16.9%) for previous latanoprost and travoprost treatment, respectively (all P<0.0001). IOP reduction in patients previously treated with a fixed combination was 2.7±4.0 mmHg (14.2%, P<0.0001). The most commonly reported adverse events were conjunctival hyperemia (5.2%) and eye irritation (4.7%). Tolerability was rated as “very good” or “good” by 90.1% of patients. Adherence was rated by physicians as “better than” or “equal to” previous treatment in 97.2% of patients. Conclusion: The combined studies demonstrated in a clinical practice setting, bimatoprost 0.01% lowered IOP effectively in treatment-naïve and previously treated ocular hypertension and primary open-angle glaucoma patients, and was associated with good tolerability and patient adherence over 12 weeks. Keywords: bimatoprost 0.01%, intraocular pressure, prostaglandin, bimatoprost, glaucoma treatment, switch therapy |
| format |
article |
| author |
Stevens A Iliev ME de Jong L Grobeiu I Hommer A |
| author_facet |
Stevens A Iliev ME de Jong L Grobeiu I Hommer A |
| author_sort |
Stevens A |
| title |
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_short |
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_full |
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_fullStr |
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_full_unstemmed |
A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| title_sort |
combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/da3dc5653ea84b31b93ae7785389c2bf |
| work_keys_str_mv |
AT stevensa acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT ilievme acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT dejongl acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT grobeiui acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT hommera acombinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT stevensa combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT ilievme combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT dejongl combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT grobeiui combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension AT hommera combinedanalysisoffourobservationalstudiesevaluatingtheintraocularpressureloweringabilityandtolerabilityofbimatoprost001inpatientswithprimaryopenangleglaucomaorocularhypertension |
| _version_ |
1718403834226671616 |